Phase 3 Randomized Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Brief description of study

The purpose of the trial is to determine the safety and efficacy of the pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus androgen deprivation therapy (ADT) in participants with metastatic hormone-sensitive prostate cancer (mHSPC). We want to know if one treatment is superior to another when treating participants with metastatic hormone-sensitive prostate cancer.


Clinical Study Identifier: s19-01532
ClinicalTrials.gov Identifier: NCT04191096
Principal Investigator: David R. Wise.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.